France· FR:63887327
YESCARTA 0,4 - 2 x 100 000 000 cellules, dispersion pour perfusion
A axicabtagene ciloleucel product containing axicabtagène ciloleucel, registered in France by KITE PHARMA EU (PAYS-BAS). The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Axicabtagene ciloleucel is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XL03 (axicabtagene ciloleucel), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Axicabtagene ciloleucel · ATC L01XL03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- AXICABTAGÈNE CILOLEUCEL
- Manufacturer
- KITE PHARMA EU (PAYS-BAS)
- Country
- France (FR)
- ATC code
- L01XL03
- ATC class
- Axicabtagene ciloleucel
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550574131 poche(s) EVA : éthylène vinyl acétate copolymère suremballée(s)/surpochée(s) de 68 ml avec matériel(s) de perfusion
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
58 interactions on record for axicabtagene ciloleucel.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Axicabtagene ciloleucel · interactions on record
58 records
- 28 severe
- 30 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Axicabtagene ciloleucel in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesYESCARTAKite Pharma, Inc.
- CanadaYESCARTAGILEAD SCIENCES CANADA INC
- SwitzerlandYescartaGilead Sciences Switzerland Sàrl
- CzechiaYESCARTAKite Pharma EU B.V., Hoofddorp
- SpainYESCARTA 0,4 - 2 x 10e8 CELULAS DISPERSION PARA PERFUSIONKite Pharma Eu B.V.
- FinlandYescartaKite Pharma EU B.V.
- United KingdomYescarta 40million-200million cells/68ml dispersion for infusion bagsGilead Sciences Ltd
- BelgiumYescarta 0,4–2 x 10*8 cellsKite Pharma EU
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yescarta
- Liechtenstein · Yescarta
- Norway · Yescarta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/949c1632-adb2-4a6d-929c-243df599af3f GET /v1/drugs/949c1632-adb2-4a6d-929c-243df599af3f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63887327",
"date_amm": "2018-08-23",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1299",
"substance": "AXICABTAGÈNE CILOLEUCEL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "dispersion pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about axicabtagene ciloleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.